A 52-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE 2A
STUDY ASSESSING SAFETY AND EFFICACY OF SAR442970, A DUAL ANTI-TNF-¿ AND ANTIOX40L NANOBODY® MOLECULE, FOR PRESERVATION OF PANCREATIC ¿-CELL FUNCTION IN
ADULTS AND ADOLESCENTS WITH RECENTLY DIAGNOSED TYPE 1 DIABETES
- Registry ID
- ACT18368
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- SANOFI-AVENTIS CANADA INC
- Start date
- 2025-01-31
- Last update
- 2024-12-13
Conditions
Related clinical trials
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BARICITINIB TO PRESERVE BETA CELL FUNCTION IN PARTICIPANTS NEWLY DIAGNOSED WITH TYPE 1 DIABETES AGED =1 TO <36 YEARS. (BARICADE-PRESERVE)
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BARICITINIB TO DELAY STAGE 3 TYPE 1 DIABETES IN AT-RISK PARTICIPANTS AGED =1 TO <36 YEARS (BARICADE-DELAY)
- A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE EFFICACY AND SAFETY
OF TEPLIZUMAB COMPARED WITH PLACEBO IN PARTICIPANTS 1 TO 25 YEARS OF AGE WITH
RECENTLY DIAGNOSED STAGE 3 TYPE 1 DIABETES (T1D)
- A 26-WEEK STUDY COMPARING THE EFFICACY AND SAFETY OF ONCE-WEEKLY INSULIN ICODEC AND ONCE-DAILY INSULIN GLARGINE U100, BOTH IN COMBINATION WITH INSULIN ASPART, IN ADULTS WITH TYPE 1 DIABETES
- A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLELGROUP STUDY EVALUATING THE EFFICACY AND LONG-TERM SAFETY OF TIRZEPATIDE ONCE
WEEKLY COMPARED TO PLACEBO IN ADULTS WITH TYPE 1 DIABETES AND OBESITY OR
OVERWEIGHT (SURPASS-T1D-2)
- JAK INHIBITORS TO PRESERVE C-PEPTIDE PRODUCTION IN NEW ONSET T1D: A PHASE 2 MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBTYPE-SELECTIVE JAK INHIBITORS FOR PRESERVATION OF PANCREATIC ¿ CELL FUNCTION IN NEWLY DIAGNOSED TYPE 1 DIABETES MELLITUS
View on source registry